Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia (PHN)

NCT01748877 is registered in ClinicalTrials.gov with NeurAxon Inc. as lead sponsor.

NCT NCT01748877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01748877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia (PHN)
Lead sponsor
NeurAxon Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2013
Completion date
June 30, 2014
Enrollment
188 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

post herpetic neuralgia